Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(3.85)
# 672
Out of 4,944 analysts
19
Total ratings
66.67%
Success rate
7.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITOS iTeos Therapeutics | Maintains: Equal-Weight | $12 → $11 | $10.13 | +8.59% | 7 | Aug 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $33 → $27 | $7.72 | +249.74% | 3 | Aug 7, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $26 → $25 | $10.06 | +148.51% | 3 | Aug 7, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $30 → $42 | $33.65 | +24.81% | 2 | Jul 9, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $44 | $24.42 | +80.18% | 1 | Jun 26, 2025 | |
| BCAX Bicara Therapeutics | Upgrades: Equal-Weight | $8 | $11.32 | -29.33% | 2 | May 23, 2025 | |
| MRUS Merus | Maintains: Overweight | $91 → $89 | $67.22 | +32.40% | 1 | May 8, 2025 |
iTeos Therapeutics
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $10.13
Upside: +8.59%
Xencor
Aug 7, 2025
Maintains: Overweight
Price Target: $33 → $27
Current: $7.72
Upside: +249.74%
Arcus Biosciences
Aug 7, 2025
Maintains: Overweight
Price Target: $26 → $25
Current: $10.06
Upside: +148.51%
Kiniksa Pharmaceuticals International,
Jul 9, 2025
Maintains: Overweight
Price Target: $30 → $42
Current: $33.65
Upside: +24.81%
IDEAYA Biosciences
Jun 26, 2025
Initiates: Overweight
Price Target: $44
Current: $24.42
Upside: +80.18%
Bicara Therapeutics
May 23, 2025
Upgrades: Equal-Weight
Price Target: $8
Current: $11.32
Upside: -29.33%
Merus
May 8, 2025
Maintains: Overweight
Price Target: $91 → $89
Current: $67.22
Upside: +32.40%